Article Abstract

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

Authors: Cesare Gridelli, Francesca Casaluce


Squamous non-small cell lung cancer (NSCLC) remains very difficult to treat, differing remarkably from adenocarcinoma. The knowledge of oncogene molecular markers and their specific targeted therapies have taken place in the management of adenocarcinoma only, forcing patients with squamous disease to settle for several years with convention platinum-based chemotherapy as the best first-line option. The U.S. Food and Drug Administration (FDA), differently from European Agency for Medicine (EMA) in Europe, approved necitumumab combined to first-line regimen of cisplatin plus gemcitabine in squamous patients that however remained an unpopular choice for clinical practice, due to its high side effect profile, not well balanced from limited benefit (1).